STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVRX
  4. [Form 4/A] JOHNSON & JOHNSON Amended Insider Trading Activity

Johnson & Johnson (NYSE: JNJ) discloses CVRx stock sales in Form 4/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.

Positive

  • None.

Negative

  • None.
Insider JOHNSON & JOHNSON, Johnson & Johnson Innovation - JJDC, Inc.
Role 10% Owner | 10% Owner
Sold 22,337 shs ($224K)
Type Security Shares Price Value
Sale Common Stock 6,337 $10.03 $64K
Sale Common Stock 16,000 $10.03 $160K
Holdings After Transaction: Common Stock — 4,024,861 shares (Indirect, By Johnson & Johnson Innovation - JJDC, Inc.)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JOHNSON & JOHNSON
(Last) (First) (Middle)
ONE JOHNSON & JOHNSON PLAZA
(Street)
NEW BRUNSWICK NJ 08933
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CVRx, Inc. [ CVRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
12/01/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/25/2025 S 16,000 D $10.03(1) 4,031,198 I By Johnson & Johnson Innovation - JJDC, Inc.(2)
Common Stock 11/26/2025 S 6,337 D $10.03(3) 4,024,861 I By Johnson & Johnson Innovation - JJDC, Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
JOHNSON & JOHNSON
(Last) (First) (Middle)
ONE JOHNSON & JOHNSON PLAZA
(Street)
NEW BRUNSWICK NJ 08933
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Johnson & Johnson Innovation - JJDC, Inc.
(Last) (First) (Middle)
410 GEORGE STREET
(Street)
NEW BRUNSWICK NJ 08901
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
This Amendment to the Form 4 filed on 12/01/2025 is being filed to include the sale of shares on 11/25/2025, which was inadvertently omitted from the original filing due to an administrative oversight.
Johnson & Johnson By /s/ Marc Larkins, Secretary 01/08/2026
Johnson & Johnson Innovation - JJDC, Inc. By: /s/ Jill McManus, Assistant Treasurer 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Johnson & Johnson report in this CVRx (CVRX) Form 4/A?

The amended filing reports that a Johnson & Johnson subsidiary, Johnson & Johnson Innovation - JJDC, Inc., sold 16,000 CVRx common shares on 11/25/2025 and 6,337 shares on 11/26/2025, both coded as sales.

At what prices were the CVRx shares sold by Johnson & Johnson’s JJDC unit?

For both dates, Column 4 shows a weighted average price of $10.03. The 11/25/2025 sales occurred in multiple trades between $10.00 and $10.22, and the 11/26/2025 sales occurred between $10.00 and $10.23.

How many CVRx shares does Johnson & Johnson report owning after these transactions?

Following the reported sales, the filing shows 4,024,861 shares of CVRx common stock as indirectly beneficially owned by Johnson & Johnson through its wholly owned subsidiary, Johnson & Johnson Innovation - JJDC, Inc.

Why was this Johnson & Johnson Form 4/A for CVRx filed as an amendment?

The document states it is an amendment to the Form 4 filed on 12/01/2025, submitted to include the 11/25/2025 sale of 16,000 shares, which was inadvertently omitted from the original filing due to an administrative oversight.

Who actually holds the CVRx shares reported by Johnson & Johnson in this filing?

The securities are reported as indirectly beneficially owned by Johnson & Johnson and are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., which the filing describes as a wholly owned subsidiary of Johnson & Johnson.

What is Johnson & Johnson’s relationship to CVRx according to this Form 4/A?

The relationship section indicates the reporting person is a Director of CVRx. The Form 4/A reflects the position as a director rather than as a 10% owner or officer in the checked boxes.